May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
Switching from a suppressive five-drug regimen to Genvoya and Prezista proved virologically noninferior to maintaining the initial regimen at 24 weeks and virologically superior at 48 weeks.
Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is a complete treatment in one pill that comes in the form of green capsule-shaped tablets. The dose of Genvoya used by adults with HIV is one tablet once daily with food.
In this interview, Eric Daar, M.D. discusses how the new coformulation elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) measures up to its predecessor, specifically among older adults.